Immunomodulatory and/or immunosuppressive drugs should not be stopped prior to skin tests for the assessment of drug allergy - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue British Journal of Dermatology Année : 2022

Immunomodulatory and/or immunosuppressive drugs should not be stopped prior to skin tests for the assessment of drug allergy

Résumé

The use of immunomodulatory and/or immunosuppressive therapy (IT) is increasingly common in the management of chronic inflammatory disease. Skin reactions to any drug (IT or not) are not rare in these patients, justifying allergological investigations. The influence of IT on allergological tests for drugs is not clearly described. IT cannot be interrupted due to the underlying disease. The data assessing the benefit and the safety of allergological test for drug allergy in patients under IT are missing.
Fichier non déposé

Dates et versions

hal-03464515 , version 1 (03-12-2021)

Identifiants

Citer

F. Dezoteux, S. El Mesbahi, B. Tedbirt, J. Grosjean, S. Gautier, et al.. Immunomodulatory and/or immunosuppressive drugs should not be stopped prior to skin tests for the assessment of drug allergy. British Journal of Dermatology, 2022, 186 (4), pp.742-744. ⟨10.1111/bjd.20901⟩. ⟨hal-03464515⟩
43 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More